Q1 2023 Results

Company overview Financial review Conclusions Appendix References Strengthening radioligand therapy pipeline; advancing multiple assets in clinical development INNOVATION Recent business development in RLT Discovery collaboration with Bicycle Therapeutics ■ BicycleⓇ platform employs constrained cyclic peptides - Provides variety of structural shapes/chemical diversity - May broaden the tractable target space (key differentiator from other peptide platforms) Current RLT pipeline ■ Supplements our existing vector discovery platforms Acquisition of FAP-2286 (Clovis Oncology) ■ Fibroblast Activation Protein (FAP) represents a promising RLT target in PDAC, CRC, BC, NSCLC - Frequently expressed on cancer-associated fibroblasts across cancers FAP-2286, currently developed in Ph1/2 - - Showed first signs of efficacy/favorable safety profile ■ Potential to be first-in-class, transformative RLT Selected compound (indication) Lutathera (1L GEP-NET) Phase 1 Phase 2 Phase 3 Lutathera (Pediatrics + PPGL)1 1 Lutathera (GBM)² Lutathera (ES-SCLC)² Pluvicto (mHSPC) 2 Pluvicto (mCRPC) pre-taxane 225AC-PSMA-617 3 (PCa+bone metastases) 4 NeoB (multi tumor) 5 FAP-22862,3 NSCLC non-small cell lung cancer. GEP-NET - gastroenteropancreatic neuroendocrine tumor. ES-SCLC extensive stage small cell lung metastatic castration resistant prostate cancer. 1. PPGL, pheochromocytomas and paragangliomas, are an exploratory cohort of NETTER-P. 2. Phase 1/2. PDAC - pancreatic ductal adenocarcinoma. CRC colorectal cancer. BC breast cancer. mHSPC metastatic hormone sensitive prostate cancer. mCRPC cancer. 3. Being integrated in the NVS pipeline. 10 Investor Relations | Q1 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation